Member Info for GreenManDK

You wouldn't do a rights issue for a small amount of money as its a big hassle. My interpretation of this is that this issue has caused the door to be closed for now on any potential partnership deals and they are now going to raise funds for the next 1.5years to complete the trials themselves.... means we wont see SSV for quite some time now..... i am here for the long haul so will ride it out

I managed to buy £5.4k @ 207p so hopefully that I have capitalised on this mess!

Yeah we are supposed to be a properly managed company, this is surprising. However, I am trying to buy at these new prices but cannot get a quote on HL....

Email sent, thanks for composing

I won't be able to watch as will be in meetings but is someone able to attend and summarise? I'd particularly like to hear about the responses in the Q&A as there are usually some exciting leading answers from Marku! Sax are you attending?

Yeah my transactions are showing up now

Accidently sold a decent chunk when i was doing a dummy sell to get the true market price, idiot! re bought immediately so you'll see 2 transactions and thats the reason for it, screwed myself over on the spread! absolutely furious with myself

I got a bit over excited when I saw EGM in the RNS headline and was reading about voting in the first few lines! Do we think Bayer Pharma are the front runners for a partnership deal? They certainly have a big enough market cap! $54bn!

And just got another 2 more of the same, interesting it didnt push the price up but they wouldnt give me any more than 2 clips, so 4 total. Im trying to buy £5k worth today so will try and keep buying through the afternoon to close

I just pushed us over 300. Just bought 2 £500 clips at 306p. I thought it would be good for morale if we finished over 300!! Wasnt able to buy a penny more though!

Heres the copy and paste of the redeye note. Sorry its split across 2 posts, read the lower down post first.

Like azacytidine monotherapy. Encouragingly, all patients with MDS and prior HMA failure across the dosing cohorts demonstrated an objective response, illustrating the potential for bexmarilimab to amplify the therapeutic effect of SoC treatment in these indications.

Furthermore, the first interim data from the first triplet cohort were examined, and four out of six patients in this group exhibited an objective response. The treatment in this cohort has been well-tolerated so far, with no bexmarilimab-related grade three or higher adverse events (AEs) or serious adverse events (SAEs) observed during the study. These findings are promising, and more detailed data on this unique treatment cohort are eagerly awaited.

Faron also provided insights into the development plan for bexmarilimab in these indications. The company intends to seek FDA advice in the third quarter of 2023 and aims to advance to phase II part of the BEXMAB study in the second half of 2023. By generating additional supporting data through these studies, Faron plans to file a first Biologics License Application (BLA) to the FDA in the first half of 2025.

We will return with further analysis of the clinical progression of bexmarilimab along with updated estimates and valuation in conjunction with the company’s upcoming H1 report in August.

Faron Pharmaceuticals: Positive BEXMAB Study Update

RESEARCH NOTE

2023-07-19

10:55

Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab. We are encouraged by the continued positive progress and the candidate’s favorable response to treatment in relapsed/refractory AML and MDS.

Kevin Sule

Earlier today, Faron released additional encouraging findings from their phase I/II BEXMAB study, which focuses on evaluating the potential of the company’s leading candidate, bexmarilimab, in combination with standard-of-care (SoC) treatment for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This comprehensive study consists of two distinct arms: a doublet arm where patients receive bexmarilimab treatment combined with azacytidine, and a triplet arm where patients receive bexmarilimab treatment in conjunction with both azacytidine and venetoclax.

Each arm is structured into three dose cohorts, with five patients in each cohort, receiving different doses of bexmarilimab. The dose cohorts are as follows: the first receives 1mg/kg, the second receives 3mg/kg, and the third receives 6mg/kg. These investigations aim to assess the safety and effectiveness of the treatment regimens and potentially offer new avenues for managing AML and MDS in relapsed or refractory cases.

During the European Hematology Association (EHA) 2023 Hybrid Congress on 9 June 2023, Faron presented promising biomarker data, revealing sustained engagement of Clever-1 targets in the bone marrow tumor microenvironment. The data showed notable increases in key cell types, namely T and NK cells, which effectively curtailed cancer growth and spread. Additionally, treatment with bexmarilimab led to heightened human leucocyte antigen (HLA-DR) gene expression in leukemic blasts, signifying improved immune recognition and eradicating malignant cells. Excitingly, the updated preliminary efficacy data demonstrated objective responses (OR) in 5 out of 10 patients across the first and second dose cohorts (1 or 3mg/kg doublet cohort). This was evident by a reduction in bone marrow blasts, leading to complete (CR) or partial remissions (PR).

Building on these promising results, Faron shared new interim efficacy data from the BEXMAB study. Specifically, the preliminary data from the third dose cohort (6mg/kg bexmarilimab + azacytidine) in the doublet arm were examined. Three of five patients in this cohort achieved complete remission of blasts in the bone marrow (mCR). One of these patients also experienced a complete recovery of blood counts, indicating the enhanced efficacy of Bexmarilimab at higher dosages.

Across all three doublet dosing cohorts (1, 3, and 6 mg/kg), 15 objective responses (ORs) were observed, with eight patients demonstrating positive outcomes. Four of these eight patients had previously experienced treatment failure with standard-of-care (So

Would it be normal practice to have a partnership in place before this or does that just depend on how the company is funded?

Topped up again, only mentioning it because they’re reporting it as a sell when in facts it’s a buy. I never understand why they do that

I knew you’d top up as well Sax! Nice one! I’ve just picked up a few more in my SIPP as well now.

Well I just topped up £1500 @231p, in for a penny etc… I’m fully committed to this investment and am well aware the road to comercialisation won’t be a simple or quick one!

Putin looks scared! The ultimate final level of Call

Of Duty going to be played out at Putins black palace!

Did anyone ever find out how Absolute Precision were involved? It was all a bit hush hush at the time. Will they be referenced in the DFS if that is ever released?

I’m quite surprised to see there has been no price movement today given this is the first real announcement indicating commercialisation of Bex!